

Canada's Premiere Virtual Cardiovascular Symposium

CardioMet'25 will be Canada's premiere, virtual cardiovascular symposium. Aimed at cardiovascular specialists, this multi-day virtual conference will highlight topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting edge science, CardioMet'25 will be unlike any other cardiovascular conference in Canada.

31st JANUARY
7th FEBRUARY 2025

12:00 – 6:00 pm EST

Program Themes

31st JANUARY 2025

- ARRHYTHMIA
- HEART FAILURE
- CARDIOMYOPATHIES AND CARDIOGENIC SHOCK

7th FEBRUARY 2025

- CHRONIC CORONARY SYNDROMES
- CARDIOMETABOLIC
- POT POURRI

Register Now!

Accreditation:

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the University of Calgary Office of Continuing Medical Education and Professional Development. This activity has been approved for a maximum of 10.5 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™.

CardioMet^{'25}

Scientific Planning Committee



Margot Davis

MD, FRCP, FCCS
University of British Columbia



Anique Ducharme

MD, MSc, FRCP, FCCS
Montreal Heart Institute



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)
University of Toronto



Jay Udell

MD, MPH, FRCPC
Toronto General Hospital

Overall Learning Objectives:

- ✓ Discuss the latest advances in cardiovascular risk factor management and prevention
- ✓ Explain new developments in the management of heart failure, cardiomyopathies and arrhythmia
- ✓ Explore advances in chronic coronary syndromes and cardiometabolic medicine

Registration

Visit: www.ccrnmd.com

For inquiries regarding this program, please contact info@ccrnmd.com.



This program has received an educational grant from:

Impact Level: Pfizer, Egg Farmers of Canada, Novartis, Merck
Benefactor Level: Amgen, AstraZeneca, Bayer, Anthos
Therapeutics



Faculty

12:00 - 12:10 Welcome and opening remarks **Milan Gupta**

KEYNOTE ADDRESS

12:10 - 12:35 Toward 2030: Reengineering cardiovascular clinical trials in a changing world **Paul W. Armstrong**

12:35 - 12:45 DISCUSSION

THEME ONE ARRHYTHMIA

12:45 - 1:03 How to manage post-operative atrial fibrillation **William McIntyre**

1:03 - 1:21 AF: antiarrhythmic therapy or ablation? **Laurent Macle**

1:21 - 1:39 Factor XI/XIa inhibitors – are they the future? **Jeffrey Weitz**

1:39 - 1:57 PVC's/VT – when to ablate? **Isabelle Nault**

1:57 - 2:20 DISCUSSION

Learning Objectives

- Explore necessary changes in cardiovascular clinical trials to meet current and evolving needs and trends
- Describe prevention and management strategies for post-operative atrial fibrillation
- Determine when to ablate vs the role of antiarrhythmic therapy for AF
- Explore the role of Factor XI/XIa in AF stroke prevention and bleeding
- Identify when ablation is appropriate for PVC's/VT

2:20 - 2:45 **REFRESHMENT BREAK**

THEME TWO HEART FAILURE

2:45 - 3:03 HFpEF and the obesity/inflammation continuum **Mark Petrie**

3:03 - 3:21 HFpEF: what's on the horizon? **Scott Solomon**

3:21 - 3:39 Pulmonary hypertension: a primer for cardiologists **Lisa Mielniczuk**

3:39 - 3:57 Challenging cases in HFrEF **Margot Davis**

3:57 - 4:20 DISCUSSION

Learning Objectives

- Examine the impact of obesity and inflammation for patients with HFpEF
- Explore evolving treatment options for HFpEF
- Define the causes and treatment strategies for pulmonary hypertension
- Apply best practices for the management of challenging HFrEF cases

THEME THREE CARDIOMYOPATHIES & CARIOGENIC SHOCK

4:20 - 4:38 Investigating LVH: treatment advances in hypertrophic cardiomyopathy **Patrick Garceau**

4:38 - 4:56 Infiltrative cardiomyopathies: sarcoid and amyloid **Rola Khedraki**

4:56 - 5:14 Cardiogenic shock – early detection and planning ahead **Adriana Luk**

5:14 - 5:32 Cardio-rheumatology – Understanding the biology and monitoring for anti-inflammatory therapies in cardiology **Brittany Weber**

5:32 - 5:55 DISCUSSION

Learning Objectives

- Define new treatment options for patients with hypertrophic cardiomyopathy
- Explore the diagnostic and management strategies for infiltrative cardiomyopathies
- Explain strategies for managing cardiogenic shock to improve outcomes
- Describe the biology and need for monitoring of anti-inflammatory therapies in cardio-rheumatology

5:55 - 6:00 **MEETING CLOSE**

Faculty

12:00 - 12:10 Welcome and opening remarks **Milan Gupta**

KEYNOTE ADDRESS

12:10 - 12:30 Womens' health and cardiovascular medicine **Martha Gulati**

12:30 - 12:40 DISCUSSION

THEME ONE CHRONIC CORONARY SYNDROMES

12:40 - 12:58 DM and CKD management in patients with ASCVD **Matthew R. Weir**

12:58 - 1:16 Obesity management in patients with ASCVD **Milan Gupta**

1:16 - 1:34 How to best investigate stable CAD in 2025 **Michael E. Farkouh**

1:34 - 1:52 Stable multivessel disease: OMT, PCI or CABG? **John Mancini**

1:52 - 2:15 DISCUSSION

Learning Objectives

- Examine issues unique to women in the prevention and management of cardiovascular disease
- Explain how to manage diabetes and CKD in patients with ASCVD
- Explain how to manage obesity in patients with ASCVD
- Identify effective methods for detecting coronary artery disease
- Determine appropriate treatment or intervention for patients with stable multivessel disease

2:15 - 2:45 **REFRESHMENT BREAK**

THEME TWO CARDIOMETABOLIC

2:45 - 3:03 The role of dietary cholesterol in ASCVD **Kristina S. Petersen**

3:03 - 3:21 LDL-C: how low can and should we go? **Marc Sabatine**

3:21 - 3:39 Triglycerides: the forgotten risk marker **Liam Brunham**

3:39 - 3:57 Elevated Lp(a): how to manage in primary and secondary prevention **Michelle O'Donoghue**

3:57 - 4:20 DISCUSSION

Learning Objectives

- Examine the impact of dietary cholesterol on ASCVD
- Determine the appropriate LDL-C level for at-risk patients
- Explore current and future treatment options for risk reduction with elevated triglycerides
- Explore the potential of Lp(a) lowering in primary and secondary prevention

THEME THREE POT POURRI

4:20 - 4:38 MINOCA/INOCA: diagnosis and management **Tara Sedlak**

4:38 - 4:56 POTS: diagnosis and management **Satish R. Raj**

4:56 - 5:14 Adult congenital heart disease for the general cardiologist **Jasmine Grewal**

5:14 - 5:32 Cardio-oncology for the general cardiologist **Dinesh Thavendiranathan**

5:32 - 5:55 DISCUSSION

Learning Objectives

- Describe an approach to diagnosis and treatment of MINOCA
- Explain when and how to suspect and confirm a diagnosis of POTS
- Explain the role of general cardiologist in patients with congenital heart disease
- Explore clinical lessons for general cardiologists managing patients with cancer

5:55 - 6:00 **MEETING CLOSE**



Registration
Visit: www.ccrnmd.com

Register Now!

